Attorneys in an Actos bladder cancer lawsuit have blamed manufacturer Takeda Pharmaceuticals for putting Actos profits ahead of patient safety. Lawyers alleged that Takeda executives knew as early as 2004 that their type 2 diabetes medicine Actos could greatly increase the risks of patients developing bladder cancer, but did not issue a warning until 7 years later in order to protect profits.
The Actos lawsuit is the seventh to go to trial and was filed by Frances Wisniewski, who developed bladder cancer after using Actos for her diabetes. A jury recently levied a $9 billion decision against Actos in a Louisiana court room, issuing the punitive damages to deter future wrongdoing from the company.
As many as 8,000 Actos lawsuits have been filed against Takeda for failing to warn doctors and patients of the increased risks of bladder cancer associated with Actos. A five-year study found that patients who use Actos for at least 1 year are 40% more likely to develop bladder cancer than patients who use an alternative bladder cancer medication.